Originally published as JCO Early Release 10.1200/JCO.2005.05.5160 on July 31 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weischer, M. Articles by Nordestgaard, B. G. Search for Related Content PubMed PubMed Citation Articles by Weischer, M. Articles by Nordestgaard, B. G. Related Articles Related Correspondence

Increased Risk of Breast Cancer Associated With CHEK2*1100delC

Maren Weischer, Stig Egil Bojesen, Anne Tybjærg-Hansen, Christen Kirk Axelsson, Børge Grønne Nordestgaard

From the Department of Clinical Biochemistry, Herlev University Hospital; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital; The Copenhagen City Heart Study, Bispebjerg University Hospital; and Department of Breast Surgery, Herlev University Hospital, University of Copenhagen, Copenhagen, Denmark

Address reprint requests to Børge G. Nordestgaard, Professor and Chief Physician, Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark; e-mail: brno{at}herlevhosp.kbhamt.dk

Purpose: CHEK2*1100delC heterozygosity has been associated with increased risk of breast, prostate, and colorectal cancer in case-control studies. We tested the hypothesis that CHEK2*1100delC heterozygosity in the general population increases the risk of cancer in general, and breast, prostate, and colorectal cancer in particular.

Patients and Methods: We performed a prospective study of 9,231 individuals from the Danish general population, who were observed for 34 years, and we performed a case-control study including 1,101 cases of breast cancer and 4,665 controls.

Results: Of the general population, 0.5% were heterozygotes and 99.5% were noncarriers. In the prospective study, multifactorially adjusted hazard ratios by CHEK2*1100delC heterozygosity versus noncarriers were 1.2 (95% CI, 0.7 to 2.1) for all cancers, 3.2 (95% CI, 1.0 to 9.9) for breast cancer, 2.3 (95% CI, 0.6 to 9.5) for prostate cancer, and 1.6 (95% CI, 0.4 to 6.5) for colorectal cancer. In the case-control study, age-matched odds ratio for breast cancer by CHEK2*1100delC heterozygosity versus noncarriers was 2.6 (95% CI, 1.3 to 5.4). The absolute 10-year risk of breast cancer in CHEK2*1100delC heterozygotes amounted to 24% in women older than 60 years undergoing hormone replacement therapy, with a body mass index of 25 kg/m² or higher.

Conclusion: CHEK2*1100delC heterozygosity is associated with a three-fold risk of breast cancer in women in the general population.

published online ahead of print at www.jco.org on July 31, 2006.

Supported by the Michaelsen Foundation, the Danish Heart Foundation, Chief Physician Johan Boserup and Lise Boserups Fund, the Danish Medical Research Council, the Research Fund at Rigshospitalet, Copenhagen University Hospital, and Copenhagen County.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• CHEK2 Mutation and Hereditary Breast Cancer
  Natalia Bogdanova, Sergei Feshchenko, Cezary Cybulski, and Thilo Dörk
  JCO 2007 25: 26 [Full Text]
• CHEK2 Mutation and Hereditary Breast Cancer
  Natalia Bogdanova, Sergei Feshchenko, Cezary Cybulski, and Thilo Dörk
  JCO 2007 25: 26 [Full Text]
• CHEK2 Screening: Do Not Think So Globally Yet
  Maria D. Iniesta and Sofia D. Merajver
  JCO 2008 26: 3092 [Full Text]

This article has been cited by other articles:

				S. L. Dombernowsky, M. Weischer, K. H. Allin, S. E. Bojesen, A. Tybjjrg-Hansen, and B. G. Nordestgaard Risk of Cancer by ATM Missense Mutations in the General Population J. Clin. Oncol., June 20, 2008; 26(18): 3057 - 3062. [Abstract] [Full Text] [PDF]

				M. D. Iniesta and S. D. Merajver CHEK2 Screening: Do Not Think So Globally Yet J. Clin. Oncol., June 20, 2008; 26(18): 3092 - 3092. [Full Text] [PDF]

				M. Weischer, S. E. Bojesen, C. Ellervik, A. Tybiaerg-Hanson, and B. G. Nordestgaard In Reply J. Clin. Oncol., June 20, 2008; 26(18): 3093 - 3094. [Full Text] [PDF]

				M. Weischer, S. E. Bojesen, C. Ellervik, A. Tybjaerg-Hansen, and B. G. Nordestgaard CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls J. Clin. Oncol., February 1, 2008; 26(4): 542 - 548. [Abstract] [Full Text] [PDF]

				K. Offit and J. E. Garber Time to Check CHEK2 in Families With Breast Cancer? J. Clin. Oncol., February 1, 2008; 26(4): 519 - 520. [Full Text] [PDF]

				M. Fatouros, G. Baltoyiannis, and D. H. Roukos The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33. [Abstract] [Full Text] [PDF]

				N. Bogdanova, S. Feshchenko, C. Cybulski, and T. Dork CHEK2 Mutation and Hereditary Breast Cancer J. Clin. Oncol., July 1, 2007; 25(19): e26 - e26. [Full Text] [PDF]

				D. D. Orsted, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population J. Exp. Med., June 11, 2007; 204(6): 1295 - 1301. [Abstract] [Full Text] [PDF]

				S. A. Narod and H. T. Lynch CHEK2 Mutation and Hereditary Breast Cancer J. Clin. Oncol., January 1, 2007; 25(1): 6 - 7. [Full Text] [PDF]